Compressed Medicated Chewing Gum with Lysozyme Hydrochloride and Ascorbic Acid for Xerostomia Relief and Oral Health Support: Formulation Development, Optimization, In Vitro and In Vivo Evaluation
Pharmaceutics · 07.06.2026 · 18 (6) · 700
DOI: 10.3390/pharmaceutics18060700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 07.06.2026. Verfasst von Yuliia Maslii und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, L…. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education and Science of the Republic of Lithuania, Research Council of Lithuania, Ministry of Education, Science and Sport of the Republic of Lithuania.
Themen: Mundpflege
Abstract (Originalsprache)
Background
Existing therapies for xerostomia are primarily symptomatic, providing temporary mucosal hydration without addressing underlying pathological changes in the oral cavity. In this context, medicated chewing gums containing ascorbic acid and lysozyme hydrochloride offer a promising approach, combining antimicrobial, antioxidant, and trophic effects with physiological salivary stimulation and prolonged local delivery.
Methods
For the development of compressed chewing gum formulation, the physicochemical (particle size distribution, moisture absorption capacity, and microscopic characteristics) and technological (flowability, angle of repose, bulk and tapped density, Carr’s index (CI), and Hausner ratio (HR)) properties of the active substances and their formulations with excipients were evaluated. Pharmacological activity was assessed in an atropine-induced xerostomia rat model.
Results
The physical mixture of all components showed inferior flow properties compared with the formulation containing pre-granulated lysozyme hydrochloride, as evidenced by higher Carr’s index and Hausner ratio values (CI = 17, HR = 1.20 vs. CI = 13, HR = 1.14), indicating improved processability after pre-granulation. The effect of relative humidity during formulation was also assessed, with an optimal level of 40% required to ensure process stability due to the hygroscopic nature of the components. Based on these data, technological approaches ensuring processability were established, including wet pre-granulation of lysozyme hydrochloride and premixing of ascorbic acid to reduce oxidation risk. These approaches resulted in an optimized compression mass with excellent flowability (CI = 8, HR = 1.09), suitable for the preparation of medicated chewing gum. An optimal compression force (7 kN) ensured suitable rheological and textural properties, resulting in rapid and nearly complete release of the active ingredients from the medicated chewing gum, consistent with kinetic analysis. In vivo studies using an atropine-induced xerostomia rat model demonstrated that the combination of ascorbic acid and lysozyme hydrochloride significantly increased salivary secretion (2.17-fold vs. control pathology group) and reduced salivary gland mass coefficients (by 13–18% compared with the control pathology group and groups receiving individual active ingredients), alongside improvement of oxidative stress markers, including a reduction in TBA-reactants (by 51.6%) and an increase in catalase activity (by 51.0%).
Conclusions
The developed medicated chewing gum showed favorable technological properties, efficient release of active ingredients, and anti-xerostomic activity in vivo, indicating its potential for xerostomia relief and oral health support.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
- Department of Industrial Technology of Medicines and Cosmetics, National University of Pharmacy, 61002 Kharkiv, Ukraine.
- Institute of Pharmaceutical Technologies, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
ORCID-Profile: Yuliia Maslii, Jurga Bernatoniene
Förderung
- Ministry of Education and Science of the Republic of Lithuania
- Research Council of Lithuania
- Ministry of Education, Science and Sport of the Republic of Lithuania
Zitieren
APA
Maslii, Y., Herbina, N., Ruban, O., & Bernatoniene, J. (2026). Compressed Medicated Chewing Gum with Lysozyme Hydrochloride and Ascorbic Acid for Xerostomia Relief and Oral Health Support: Formulation Development, Optimization, In Vitro and In Vivo Evaluation. Pharmaceutics, 18(6), 700. https://doi.org/10.3390/pharmaceutics18060700
Vancouver
Maslii Y, Herbina N, Ruban O, Bernatoniene J. Compressed Medicated Chewing Gum with Lysozyme Hydrochloride and Ascorbic Acid for Xerostomia Relief and Oral Health Support: Formulation Development, Optimization, In Vitro and In Vivo Evaluation. Pharmaceutics. 2026;18(6):700. doi:10.3390/pharmaceutics18060700
BibTeX
@article{Maslii2026,
author = {Maslii, Yuliia and Herbina, Nataliia and Ruban, Olena and Bernatoniene, Jurga},
title = {Compressed Medicated Chewing Gum with Lysozyme Hydrochloride and Ascorbic Acid for Xerostomia Relief and Oral Health Support: Formulation Development, Optimization, In Vitro and In Vivo Evaluation},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {6},
pages = {700},
doi = {10.3390/pharmaceutics18060700}
}
EUVIMED